34 results about "A-Factor Receptor" patented technology

The invention provides synthetic heparin-binding growth factor analogs of formulas I or II as given in the specification, having two peptide chains branched from a dipeptide branch moiety composed of at least one and preferably two trifunctional amino acid residues, which peptide chain or chains bind a heparin-binding growth factor receptor. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.

The present invention provides compositions and methods for the regulation of cytokine signaling through the Tumor Necrosis Factor (TNF) pathway. Specifically, the invention provides a novel gene, polypeptide and related compositions and methods for the regulation of ectodomain shedding. In preferred embodiments, methods and compositions for the regulation of TNF Type-1 Receptor ectodomain shedding are provided. The present invention finds use in therapeutics, diagnostics, and drug screening applications.

The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.

The invention provides proliferative response indicator cell having a vertebrate cell having a luciferase encoding nucleic acid and a heterologous proliferation factor receptor encoding nucleic acid, wherein each of the encoding nucleic acids are operationally linked to expression elements for co-expression of a luciferase polypeptide and a heterologous proliferation factor receptor. The invention also provides a method of determining a cell proliferative response to a proliferation factor. The method includes: (a) contacting a vertebrate cell expressing luciferase and a proliferation factor receptor with a proliferation factor for sufficient time for the proliferation factor to bind to the proliferation factor receptor; (b) culturing the contacted cell expressing luciferase for at least one generation, and (c) measuring the amount of light emission, wherein the luciferase expression is driven from a promoter non-responsive to the proliferation factor and the light emission directly correlates with proliferation factor-mediated cell proliferation. The proliferation factor can be a growth factor, a cytokine or a hormone or an agonist or antagonist thereof. The methods of the invention additionally include determining the effect of an inhibitor of the proliferation factor. Cells used in the method are contacted with a proliferation factor in the presence of a sample suspected of containing an inhibitor of the proliferation factor. The inhibitor can be neutralizing antibody, or binding fragment thereof, to the proliferation factor. The methods of the invention also are applicable as an indicator of cell health or viability. The invention further provides a diagnostic system. The diagnostic system includes a plurality of different vertebrate cell lines each encoding a luciferase gene and a different proliferation factor receptor, the luciferase gene being operationally linked to a promoter non-responsive to a proliferation factor bound by the proliferation factor receptor, wherein light emission from each of the different cell lines being characterized as directly correlating with proliferation factor-mediated cell proliferation.

Engineered orthogonal cytokine receptor / ligand pairs, and methods of use thereof, are provided.

Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-beta 3, receptors of cytokines of the TG beta family, or HIF-1 alpha.

This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.

The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.

In certain embodiments, the invention relates to methods of modulating homing of T cells to the pancreas. Such methods comprise contacting the cells with an agonist or an antagonist of the chemokine CCL21, or with an agonist or an antagonist of a chemokine receptor of the T cells. In other embodiments, the invention relates to methods of treating an individual suffering from insulin-dependent diabetes. Such methods comprise administering to the individual an antagonist of the chemokine CCL21 or a chemokine receptor of the T cells. In yet other embodiments, the invention relates to methods of preventing or reducing the onset of insulin-dependent diabetes in an individual. Such methods comprise administering to the individual an antagonist of the chemokine CCL21 or a chemokine receptor of the T cells.

A novel examination method for accurately evaluating the effectiveness of treatment with an anticancer drug for the administration of the anticancer drug targeting a tumor-associated factor receptor is provided. In order to evaluate the effectiveness of trastuzumab (Herceptin™) of an anticancer drug, it was found to be meaningful to examine the expression of MUC4, that is, a substance which interacts with HER2 / c-erbB-2 belonging to the epidermal growth factor receptor family on the surface of and / or within the cell membrane. From this fact, in order to treat various cancers with an anticancer drug targeting the tumor-associated factor receptors, it was found to be meaningful to detect previously the expression of intracellular ligands against the receptors. The finding completes the present invention.

The invention relates to a polypeptide which can competitively bind EGFR to inhibit EGF-promoting tumor cell proliferation, and belongs to the technical field of biological medicine. An extracellulardomain EGFR-ECD of the epidermal cell growth factor receptor is taken as a target molecule, a phage display technology is used for panning, and EGF is used as an effective component to specifically elute the bacteriophage which is bound with the target molecule to obtain a bioactive polypeptide TUZG14; proved by the method, the bioactive polypeptide TUZG14 obviously inhibits a proliferation process of gastric cancer cells caused by EGF; the polypeptide sequence has the advantages of short polypeptide sequence, easy synthesis and large-scale production, can inhibit the growth-promoting effect of EGF, has the potential for subsequent development as an anti-cancer medicament, and has important application value in the research and development of anti-cancer drugs.

Provided are compositions and methods for inhibiting cell growth. The cells that are targeted by the compositions and methods of the invention express an antigen, a mimotope of the antigen, or a CXCR4 chemokine receptor. The method entails administering to an individual a polynucleotide encoding an immunoglobulin Fc and an antigen expressed by the cells or a mimotope of the antigen. The method also involves administering to the individual a composition which contains a polynucleotide encoding an immunoglobulin Fc and an antagonist peptide of a CXCR4 chemokine receptor expressed by the cells. Also provided are proteins encoded by the polynucleotides.

The invention discloses an EGFR-oriented monoclonal antibody modified PAMAM self-assembled transgenic composition and applications thereof. The invention provides a composition for nucleic acid transgenosis, which is prepared by compounding a polyamidoamine-dendritic polymer of which the tail end is provided with amines, an EGFR-oriented monoclonal antibody, and a nucleic acid. The composition disclosed by the invention has the following advantages that 1) by taking an epidermal growth factor receptor (EGFR) as a therapeutic target, and using a monoclonal antibody and tumor cell EGFR induced endocytosis, the targeting of a PAMAM carrier to cells is increased; 2) through the modification of PAMAM by the monoclonal antibody (mAb), the ultra-strong positive charge intensity of the PAMAM carrier can be reduced, thereby facilitating the reduction of occurrence of cytotoxicity and hemolysis phenomena; and 3) an mAb / PAMAM G5 / DNA composition is prepared by using a self-assembling method, and compared with chemical synthesis, the molecular self-assembling method can carry out modification on a system more conveniently and flexibly, and keep the bioactivity of ligands.

The present invention relates to benzothiophene sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

The present invention relates to novel phosphorous derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

The present application describes modulators of chemokine receptor activity of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.

This invention relates to novel nucleic acid molecules coding for opioid growth factor receptors. In particular, the present invention provides isolated nucleic acid molecules coding for human and rat OGF receptors. Antisense molecules, expression vectors and host cells, isolated proteins encoded by such nucleic acid molecules, antibodies directed against such proteins, as well as pharmaceutical compositions derived therefrom are also included. The invention further provides methods of modulating cell growth by using the isolated nucleic acid molecules, the antisense molecules and the antibodies directed against the encoded proteins.

The invention belongs to the biology medicine field, and relates to a fiber growth factor receptor (FGFR)-mediated vascular targeted liposome carrier, a preparation method thereof and an application thereof. The invention aims at solving the technical problem of proving a cationic liposome with high transfection efficiency and tumor vascular targeting. The targeted liposome is prepared by using the components with the following mixture ratios: the mixture ration of DOTAP, cholesterol and tb FGF polypeptide is: the mol ratio of the DOTAP to the cholesterol equals to 2:1-2, and the weight of the tb FGF polypeptide is 10-80 percent of the total weight of the DOTAP and the cholesterol. The liposome can be combined with the FGF receptor (FGFR) on the surface of tumor new-generated vascular cells particularly, and can realize the preparation method thereof and the application of tumor vascular targeting therapy by wrapping up various micromolecule anti-tumor drugs, therapy genes and adenoviral vectors carrying therapy genes.

This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.